Menopausal Disorders Drug Development Pipeline Review, 2018

Home/Menopausal Disorders Drug Development Pipeline Review, 2018

Menopausal Disorders Drug Development Pipeline Review, 2018

Drug Discovery, Pharmacy, Drug Pipeline, Pharma & Healthcare

Publication ID:

GBI0618003

Publication Date:

June 29, 2018

Pages:

Publisher:

GBI Research

Region:

Global

$3,995.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Menopausal Disorders Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for menopausal disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for postmenopausal osteoporosis, vaginal atrophy and vasomotor symptoms of menopause, and features dormant and discontinued products.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. There are 20 products in development for this indication.

Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to the body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence.

Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. There are five products in development for this indication.

Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders. There are 12 products in development for this indication.

Molecular targets acted on by products in development for menopausal disorders include tumor necrosis factor ligand superfamily member 11, parathyroid hormone receptor and progesterone receptor. Companies operating in this pipeline space include Amgen, TherapeuticsMD and Ipsen.

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Menopausal Disorders Report Coverage 7
2.2 Post Menopausal Osteoporosis - Overview 7
2.3 Vaginal Atrophy (Atrophic Vaginitis) - Overview 7
2.4 Vasomotor Symptoms of Menopause (Hot Flashes) - Overview 7
3 Therapeutics Development 8
3.1 Post Menopausal Osteoporosis 8
3.2 Vaginal Atrophy (Atrophic Vaginitis) 12
3.3 Vasomotor Symptoms of Menopause (Hot Flashes) 15
4 Therapeutics Assessment 18
4.1 Post Menopausal Osteoporosis 18
4.2 Vaginal Atrophy (Atrophic Vaginitis) 24
4.3 Vasomotor Symptoms of Menopause (Hot Flashes) 29
5 Companies Involved in Therapeutics Development 35
5.1 Post Menopausal Osteoporosis 35
5.2 Vaginal Atrophy (Atrophic Vaginitis) 41
5.3 Vasomotor Symptoms of Menopause (Hot Flashes) 43
6 Dormant Projects 46
6.1 Post Menopausal Osteoporosis 46
6.2 Vaginal Atrophy (Atrophic Vaginitis) 47
6.3 Vasomotor Symptoms of Menopause (Hot Flashes) 48
7 Discontinued Products 49
7.1 Post Menopausal Osteoporosis 49
7.2 Vasomotor Symptoms of Menopause (Hot Flashes) 49
8 Product Development Milestones 50
8.1 Post Menopausal Osteoporosis 50
8.2 Vaginal Atrophy (Atrophic Vaginitis) 65
8.3 Vasomotor Symptoms of Menopause (Hot Flashes) 68
9 Appendix 83
9.1 Methodology 83
9.2 Coverage 83
9.3 Secondary Research 83
9.4 Primary Research 83
9.5 Expert Panel Validation 83
9.6 Contact Us 84
9.7 Disclaimer 84

List of Tables
1.1 List of Tables
Table 1: Number of Products under Development for Post Menopausal Osteoporosis 8
Table 2: Number of Products under Development by Companies, Post Menopausal Osteoporosis 9
Table 3: Products under Development by Companies, Post Menopausal Osteoporosis 10
Table 4: Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis) 12
Table 5: Number of Products under Development by Companies, Vaginal Atrophy (Atrophic Vaginitis) 13
Table 6: Products under Development by Companies, Vaginal Atrophy (Atrophic Vaginitis) 14
Table 7: Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes) 15
Table 8: Number of Products under Development by Companies, Vasomotor Symptoms of Menopause (Hot Flashes) 16
Table 9: Products under Development by Companies, Vasomotor Symptoms of Menopause (Hot Flashes) 17
Table 10: Number of Products by Stage and Target, Post Menopausal Osteoporosis 19
Table 11: Number of Products by Stage and Mechanism of Action, Post Menopausal Osteoporosis 20
Table 12: Number of Products by Stage and Route of Administration, Post Menopausal Osteoporosis 22
Table 13: Number of Products by Stage and Molecule Type, Post Menopausal Osteoporosis 23
Table 14: Number of Products by Stage and Target, Vaginal Atrophy (Atrophic Vaginitis) 25
Table 15: Number of Products by Stage and Mechanism of Action, Vaginal Atrophy (Atrophic Vaginitis) 26
Table 16: Number of Products by Stage and Route of Administration, Vaginal Atrophy (Atrophic Vaginitis) 28
Table 17: Number of Products by Stage and Molecule Type, Vaginal Atrophy (Atrophic Vaginitis) 28
Table 18: Number of Products by Stage and Target, Vasomotor Symptoms of Menopause (Hot Flashes) 30
Table 19: Number of Products by Stage and Mechanism of Action, Vasomotor Symptoms of Menopause (Hot Flashes) 31
Table 20: Number of Products by Stage and Route of Administration, Vasomotor Symptoms of Menopause (Hot Flashes) 33
Table 21: Number of Products by Stage and Molecule Type, Vasomotor Symptoms of Menopause (Hot Flashes) 34
Table 22: Post Menopausal Osteoporosis - Pipeline by Amgen Inc, 35
Table 23: Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma Inc, 36
Table 24: Post Menopausal Osteoporosis - Pipeline by GL Pharm Tech Corp, 36
Table 25: Post Menopausal Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, 37
Table 26: Post Menopausal Osteoporosis - Pipeline by Ipsen SA, 37
Table 27: Post Menopausal Osteoporosis - Pipeline by Lupin Ltd, 38
Table 28: Post Menopausal Osteoporosis - Pipeline by Luye Pharma Group Ltd, 38
Table 29: Post Menopausal Osteoporosis - Pipeline by NIBEC, 39
Table 30: Post Menopausal Osteoporosis - Pipeline by Oncobiologics Inc, 39
Table 31: Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, 40
Table 32: Post Menopausal Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, 40
Table 33: Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Ligand Pharmaceuticals Inc, 41
Table 34: Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Medinova AG, 41
Table 35: Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Mithra Pharmaceuticals SA, 42
Table 36: Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD Inc, 42
Table 37: Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by EndoCeutics Inc, 43
Table 38: Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by MenoGeniX Inc, 43
Table 39: Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Mithra Pharmaceuticals SA, 44
Table 40: Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Ogeda SA, 44
Table 41: Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Pherin Pharmaceuticals Inc, 45
Table 42: Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by TherapeuticsMD Inc, 45
Table 43: Post Menopausal Osteoporosis - Dormant Projects, 46
Table 44: Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, 47
Table 45: Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects, 48
Table 46: Post Menopausal Osteoporosis - Discontinued Products, 49
Table 47: Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products, 49

List of Figures
1.2 List of Figures
Figure 1: Number of Products under Development for Post Menopausal Osteoporosis 8
Figure 2: Number of Products under Development by Companies, Post Menopausal Osteoporosis 9
Figure 3: Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis) 12
Figure 4: Number of Products under Development by Companies, Vaginal Atrophy (Atrophic Vaginitis) 13
Figure 5: Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes) 15
Figure 6: Number of Products under Development by Companies, Vasomotor Symptoms of Menopause (Hot Flashes) 16
Figure 7: Number of Products by Targets, Post Menopausal Osteoporosis 18
Figure 8: Number of Products by Stage and Targets, Post Menopausal Osteoporosis 18
Figure 9: Number of Products by Mechanism of Actions, Post Menopausal Osteoporosis 19
Figure 10: Number of Products by Stage and Mechanism of Actions, Post Menopausal Osteoporosis 20
Figure 11: Number of Products by Routes of Administration, Post Menopausal Osteoporosis 21
Figure 12: Number of Products by Stage and Routes of Administration, Post Menopausal Osteoporosis 21
Figure 13: Number of Products by Molecule Types, Post Menopausal Osteoporosis 22
Figure 14: Number of Products by Stage and Molecule Types, Post Menopausal Osteoporosis 23
Figure 15: Number of Products by Targets, Vaginal Atrophy (Atrophic Vaginitis) 24
Figure 16: Number of Products by Stage and Targets, Vaginal Atrophy (Atrophic Vaginitis) 24
Figure 17: Number of Products by Mechanism of Actions, Vaginal Atrophy (Atrophic Vaginitis) 25
Figure 18: Number of Products by Stage and Mechanism of Actions, Vaginal Atrophy (Atrophic Vaginitis) 26
Figure 19: Number of Products by Routes of Administration, Vaginal Atrophy (Atrophic Vaginitis) 27
Figure 20: Number of Products by Stage and Routes of Administration, Vaginal Atrophy (Atrophic Vaginitis) 27
Figure 21: Number of Products by Stage and Molecule Types, Vaginal Atrophy (Atrophic Vaginitis) 28
Figure 22: Number of Products by Targets, Vasomotor Symptoms of Menopause (Hot Flashes) 29
Figure 23: Number of Products by Stage and Targets, Vasomotor Symptoms of Menopause (Hot Flashes) 29
Figure 24: Number of Products by Mechanism of Actions, Vasomotor Symptoms of Menopause (Hot Flashes) 30
Figure 25: Number of Products by Stage and Mechanism of Actions, Vasomotor Symptoms of Menopause (Hot Flashes) 31
Figure 26: Number of Products by Routes of Administration, Vasomotor Symptoms of Menopause (Hot Flashes) 32
Figure 27: Number of Products by Stage and Routes of Administration, Vasomotor Symptoms of Menopause (Hot Flashes) 32
Figure 28: Number of Products by Molecule Types, Vasomotor Symptoms of Menopause (Hot Flashes) 33
Figure 29: Number of Products by Stage and Molecule Types, Vasomotor Symptoms of Menopause (Hot Flashes) 34

Companies Covered

Amgen Inc
EndoCeutics Inc
Enteris BioPharma Inc
GL Pharm Tech Corp
Intas Pharmaceuticals Ltd
Ipsen SA
Ligand Pharmaceuticals Inc
Lupin Ltd
Luye Pharma Group Ltd
Medinova AG
MenoGeniX Inc
Mithra Pharmaceuticals SA
NIBEC
Ogeda SA
Oncobiologics Inc
Paras Biopharmaceuticals Finland Oy
Pherin Pharmaceuticals Inc
TherapeuticsMD Inc
Uni-Bio Science Group Ltd

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".